July 14, 2026 -- BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) partner Eisai today announced that the US Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (sBLA) for a once weekly lecanemab irmb subcutaneous injection (US brand name: Leqembi Iqlik®) as a starting dose for the treatment of early Alzheimer's disease. The US launch is planned for late August 2026. Leqembi Iqlik is a first-of-its-kind anti-amyloid treatment worldwide, offering at-home d

GSK reported interim findings Monday for PD-1 inhibitor Jemperli (dostarlimab), which met its primary endpoint in a registrational trial involving patients with stage II/III mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) locally advanced rectal cancer. The UK pharma is planning to share the data with global regulators, including in the US, where the antibody may benefit from a speedy review. The single-arm Phase II AZUR-1 trial enrolled 154 patients to receive nine cycle

The FDA assigned a PDUFA target action date of February 28, 2027 If approved, AD109 has the potential to become the first oral pharmacologic therapy designed to address the neuromuscular root cause of upper airway collapse for the millions of people living with OSA July 14, 2026 -- Apnimed, Inc., a late stage clinical pharmaceutical company dedicated to the discovery, development, and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, t

July 14, 2026-- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") today announced that it has entered into a collaboration with Memorial Sloan Kettering Cancer Center (MSKCC) to advance a Phase II clinical study evaluating a cadonilimab-based combination regimen for the perioperative treatment of locally advanced, resectable HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma. Cadonilimab is the world's first PD-1/CTLA-4 bispecific antibody developed by Akeso. The study is be

A year after emerging from stealth, Draig Therapeutics has closed an oversubscribed $65-million series B that will go toward accelerating its neuropsychiatric drug pipeline, with depression treatment DT-101 leading the charge. DT-101 is a positive allosteric modulator of the AMPA receptor that is being evaluated for major depressive disorder (MDD). The drug is currently being studied in two Phase II trials: a global study assessing DT-101 as monotherapy and a US study testing it in the adjunct

Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset and expert team strengthen Servier's commitment to innovate for patients with high unmet medical needs. July 13, 2026 -- Servier, an independent international pharmaceutical group governed by a foundation, today announced that it has completed the acquisition of the muscular dystrophy business of Edgewise The

GSK reported positive data Friday from a B7-H3-targeting asset partnered with Hansoh Pharmaceutical Group Co. The Phase III ARTEMIS-008 trial run in China is testing the antibody-drug conjugate (ADC) risvutatug rezetecan (ris-rez) and has succeeded on its primary endpoint of overall survival (OS) in patients with advanced or relapsed small-cell lung cancer (SCLC), the UK drugmaker said. Hansoh will use the results to back its request for regulatory approval in China. GSK acquired ex-China righ

Funding to advance MindRank’s AI-native drug R&D engine and innovative pipeline, including MDR-001, an oral small-molecule GLP-1 receptor agonist in Phase III clinical development in China July 09, 2026 -- MindRank AI Ltd. (“MindRank”), a clinical-stage biotechnology company dedicated to building an AI-native engine for drug research and development, today announced the completion of a $52 million Series B financing. The round was led by a group of institutional and healthcare funds. MindRank

Application based on long-term safety and efficacy data from three ongoing studies, including adult height and additional clinical outcomes beyond linear growth, including body proportionality and arm span evaluated over long-term follow-up FDA PDUFA target action date of Feb. 28, 2027 July 13, 2026 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's supplemental New Drug Application (sNDA) for V

Boehringer Ingelheim’s Jascayd (nerandomilast) tablets have been granted marketing authorisation by the Medicines and Healthcare products Regulatory Agency (MHRA) to treat adults with idiopathic pulmonary fibrosis (IPF) and adults with progressive pulmonary fibrosis (PPF). Jascayd is the first treatment of its kind licensed for use in IPF and PPF in adults. The MHRA authorisation is based on the results of the pivotal phase 3 clinical trials involving 1,177 and 1,176 patients with IPF and PPF r